Natalizumab Biosimilar, Integrin alpha 4 Monoclonal Antibody

Natalizumab Biosimilar uses the same protein sequences as the therapeutic antibody natalizumab. Natalizumab is a monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis. Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Binds to the α4-subunit of α4b 1 and α4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptor(s).

Product Details
Species Reactivity	Human
Source	The natalizumab biosimilar CHO stable cell line
Host/Isotype	Human IgG4 kappa
Class	Monoclonal
Type	Antibody
Immunogen	The human Integrin α4
Clone	Natalizumab Biosimilar
Conjugate	Unconjugated
Purity	>95%
Molecular Weight	146.19 kDa
Protein Concentration	1 mg/ml
Formulation	Liquid
Storage Condition	4°C for short time, -20°C or -80°C for long time.
Storage Buffer	0.2 uM filtered solution, pH 6.0